NCT01267734 - Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen | Biotech Hunter

Enrollment

3,750

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

June 30, 2015

Conditions

Coronary Heart Disease

Interventions

DEVICE

Everolimus-eluting coronary stenting system (EECSS, Promus Element)

Everolimus-eluting stent

DEVICE

Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)

Zotarolimus-eluting stent

DRUG

Triple anti-platelet therapy (TAT)

100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month

DRUG

Double-dose clopidogrel anti-platelet therapy (DDAT)

100mg Aspirin QD + 150mg Clopidogrel QD for 1 month

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul